Mai, E K
Bertsch, U
Dürig, J
Kunz, C
Haenel, M
Blau, I W
Munder, M
Jauch, A
Schurich, B
Hielscher, T
Merz, M
Huegle-Doerr, B
Seckinger, A
Hose, D
Hillengass, J
Raab, M S
Neben, K
Lindemann, H-W
Zeis, M
Gerecke, C
Schmidt-Wolf, I G H
Weisel, K
Scheid, C
Salwender, H
Goldschmidt, H
Article History
Received: 3 November 2014
Revised: 12 March 2015
Accepted: 16 March 2015
First Online: 19 March 2015
Competing interests
: EKM received travel grants from Janssen-Cilag, Celgene, Onyx and Mundipharma. JD received honoraria from Janssen-Cilag, Celgene, Roche and GSK, and compensation for his consulting/advisory roles for Janssen-Cilag, Roche and GSK. MMu received honoraria from Celgene as well as travel grants from Mundipharma and Celgene. DH received compensation for his consulting/advisory role from Celgene and also received research funding from Novartis and Celgene. JH received honoraria from Celgene and Janssen-Cilag. IGHS-W received compensation for his consulting/advisroy role from Janssen-Cilag. KW received honoraria from Celgene, Janssen-Cilag and Onyx; received compensation for her consulting/advisory role at Celgene, Janssen, Onyx and Noxxon; and also received research funding from Celgene and travel grants from Celgene and Janssen-Cilag. CS received honoraria and compensation for his consulting/advisory role from Janssen-Cilag and Celgene. HS received honoraria from Celgene, Janssen-Cilag, Chugai, Novartis, Mundipharma, TEVA, Roche, Binding Site and BMS; received compensation for his consulting/advisory role at Celgene, Janssen-Cilag, BMS, Novartis and TEVA; received research funding from Celgene, Janssen-Cilag, Novartis and BMS; and also received travel grants from Celgene, Janssen-Cilag, Novartis, TEVA and Roche. HG received honoraria from Janssen-Cilag, Celgene, Novartis, Onyx and Millennium; has a consulting/advisory role at Janssen-Cilag, Celgene, Novartis, Onyx and Millennium; received compensation as a member of the speakers bureau from Janssen-Cilag, Celgene, Novartis, Onyx, Millennium and Chugai; and also received research funding from Janssen-Cilag, Celgene, Novartis and Chugai. UB, CK, MH, IWB, AJ, BS, TH, MMe, BH-D, AS, MSR, KN, H-WL, MZ and CG declare no conflict of interest.